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a b s t r a c t
Mast cell tumors (MCTs) are themost frequent round cell tumors in dogs and comprise approximately 21%
of all canine cutaneous tumors. MCTs are highly invasive and metastatic corresponding to the histological
grade. E-cadherin is an adhesion molecule expressed in epithelial cells and although it is an epithelial cel-
lular marker, studies have shown expression of E-cadherin in canine round cell tumors. To better charac-
terize the expression pattern of E-cadherin in several different histological grades of MCTs in dogs, the
expression and localization of the adhesion molecule was investigated using immunohistochemistry. For
this purpose, 18 cutaneous MCTs were classiﬁed into three histological grades, 1, 2 or 3. Clinical history
and follow-up data were available for all of the dogs. Cytoplasmic and nuclear expressions of E-cadherin
in all three types of tumors were veriﬁed by immunostaining using two different antibodies.
There was decreased E-cadherin expression in the more aggressive MCTs (Grade 3), suggesting an asso-
ciation between E-cadherin and tumor aggressiveness. Additionally, the loss of E-cadherin expression in
either the cytoplasmor nucleus inmore aggressive and undifferentiated tumor types conﬁrmed the impor-
tance of cellular adhesion in tumor behavior.
 2012 Published by Elsevier Ltd.
Introduction
Mast cell tumors (MCTs) are highly invasive and metastatic and
are the most frequent round cell tumors in dogs, comprising 16–
21% of all cutaneous tumors diagnosed (Brodey, 1970; Bostock,
1986; Rothwell et al., 1987; Misdorp, 2004). It is unclear whether
multiple MCTs represent metastatic spread or new neoplasms
(Kiupel et al., 2005; Mullins et al., 2006; Murphy et al., 2006; Pre-
ziosi et al., 2007). The molecular events and etiology of MCT devel-
opment and progression are not well elucidated but are thought to
be multifactorial (Kiupel et al., 2004; Turin et al., 2006; Scase et al.,
2006; Webster et al., 2007; Thamm and Vail, 2007). The clinical
and histological characteristics of cutaneous canine MCTs provide
useful prognostic information. MCTs were ﬁrst histologically clas-
siﬁed as Grades 1, 2 and 3 by Patnaik et al. (1984), with each grade
correlated with survival. Recently, a 2-tier classiﬁcation of MCTs
has been proposed by Kiupel et al. (2011) to more accurately pre-
dict biological course, particularly in the case of Grade 3 tumors.
Clinical and molecular studies of MCTs have focused on pre-
cisely identifying the molecular alterations for each grade and
deﬁning the biochemical and biological impact on cancer cell
proliferation and differentiation (Bostock et al., 1989; Simoes
et al., 1994; Abadie et al., 1999; Leibman et al., 2000; Lana
et al., 2000; Bergmann, 2003; Scase et al., 2006; Wu et al.,
2004; Webster et al., 2007; Strefezzi et al., 2009). The expression
proﬁles of a variety of biological markers, such as Ki67, c-Kit, Ag-
NOR, chymase and tryptase, have been investigated as potential
prognostic markers (e.g. progression, metastasis and life expec-
tancy) (Bostock et al., 1989; Simoes et al., 1994; Abadie et al.,
1999; Bergmann, 2003; Scase et al., 2006; Wu et al., 2004; Web-
ster et al., 2007).
Several studies involving human and canine neoplasms have
demonstrated that the expression of cadherins is altered during tu-
mor progression (Wijnhoven et al., 2000; Menke et al., 2001;
Bankfalvi et al., 2002; Gama et al., 2007; Brunetti et al., 2003; De
Matos et al., 2007; Polton et al., 2007), and that more aggressive
phenotypes express less E-cadherin (Torres et al., 2005; Brunetti
et al., 2003; De Matos et al., 2007; Gama et al., 2007). More recent
studies have shown that a decrease in E-cadherin expression or its
translocation from the plasma membrane to the cytoplasm and/or
nucleus can be crucial events in adherent junction destabilization
(Gloushankova, 2008; Salahshor et al., 2008; Elston et al., 2009;
Knirsh et al., 2009). In addition, it has been shown that E-cadherin
is expressed in not only canine cutaneous histiocytomas, but also
multiple other canine round cell tumors, including MCTs, plasma
cell tumors, histiocytic sarcomas and epitheliotropic lymphomas
(Ramos-Vara and Miller, 2011).
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E-cadherin is a transmembrane glycoprotein with an extracel-
lular domain that interacts with other E-cadherin molecules on
adjacent cells. It has an intracellular domain associated with a
protein complex that is comprised of a-catenin, b-catenin, c-cate-
nin and p120-catenin. Therefore, events that disrupt the complex
cadherin–catenin–cytoskeleton lead to a destabilization of cell–
cell adhesion and ultimately a reorganization of the actin cyto-
skeleton (Mareel and Leroy, 2003). It has been hypothesized that
alterations in E-cadherin expression might be a crucial event in
malignant tumor progression and growth (Wijnhoven et al.,
2000; Menke et al., 2001; Bankfalvi et al., 2002; Nowak et al.,
2008).
As E-cadherin is an important adhesion molecule, we hypothe-
sized that more aggressive MCTs would express decreased E-cad-
herin. In this study, we sought to investigate the association
between the expression and localization of E-cadherin and histo-
logical grade in cutaneous MCTs in dogs.
Materials and methods
Specimens
Eighteen cutaneous canine MCTs that had been submitted for diagnosis at the
Department of Pathology of the School of Veterinary Medicine and Animal Science
of the University of São Paulo (USP) between 2004 and 2010 were used. Each tumor
was obtained from a different dog and surgical excision was the only treatment
modality used in each case. The cases were diagnosed into three histological grades
(1, 2 or 3; n = 6 cases/grade). Clinical history and follow-up data were available for
all dogs.
Tissues were ﬁxed in 10% buffered formalin for 24–30 h and were dehydrated in
alcohol and embedded in parafﬁn. The initial diagnosis of cutaneous MCT was con-
ﬁrmed independently by two pathologists and classiﬁed according to the estab-
lished histological grading system (Patnaik et al., 1984). Medical records were
examined for each case and data recorded included dog signalment, number and
location of tumors, presence or absence of lymph node metastasis, evolution time,
recurrence interval, survival time, and cause of death. For the purposes of the study,
recurrence was deﬁned as clinical reappearance of a mass at the initial tumor site.
Metastasis was deﬁned as the development of an additional mass at a site distant
from where the original mass was resected.
Table 1
Summary of clinical ﬁndings.
Identiﬁcation
number
Tumor
grade
Dog breed Age
(years)
Gender Number
of tumors
Tumor
site
Lymph nodes
with metastasis
Tumor evolution
time (months)
Recurrence
interval
(months)
Death Time
survival
(months)
1 1 Labrador
Retriever
8 M 2 LA, S No 1 No No 26-Alive
2 1 Boxer 10 M 4 LA, C,
L, EC
No 8 No 22-
NA
22
3 1 Mixed-
breed
11 M 1 LA No 6 7 8-NA 8
4 1 Golden
Retriever
8 M 2 H/N, L No 3 No No 12-Alive
5 1 Boxer 9 F 2 H/N, L No 6 2 2-A 2
6 1 Golden
Retriever
8 M 1 PT No 20 No No 20-Alive
7 2 Dachshund 11 F 1 L Popliteal 24 10 12-A 12
8 2 Boxer 10 F 9 LA, C,
L, H/N
Submandibular 24 No 12-
NA
12
9 2 Golden
Retriever
6 M 1 C No 6 No No 14-Alive
10 2 Boxer 9 F 1 C No 2 5 9-A 9
11 2 Boxer 12 F 5 D, LT,
PT
No 6 No No 22-Alive
12 2 Boxer 7 M 1 LA No 6 No No 20-Alive
13 3 Doberman 7 F 2 EC Prescapular 4 1 1-A 1
14 3 Doberman 11 F 1 C No 30 2 7-A 7
15 3 Mixed-
breed
13 M 3 L, C Inguinal 24 1 6-A 6
16 3 Dachshund 13 M 2 LA, S No 1 2 4-A 4
17 3 Boxer 10 M 1 C No 6 5 5-A 5
18 3 Shar-Pei 11 M 1 C Inguinal,
sublumbar
2 2 2-A 2
S, scrotum; LA, lateral abdomen; LT, lateral thigh; PT, posterior thigh; H/N, head/neck; D, digits; L, limbs; C, chest; EC, ear canal; MB, mixed-breed dog; NA, death not
associated with MCT; A, death associated with MCT.
Fig. 1. Comparative analysis of survival by MCT grade. There was no signiﬁcant difference between the survival time of animals with Grades 1 and 2 MCT, but survival times
of animals with Grade 3 MCT were shorter than those with Grades 1 and 2 MCT (P = 0.0008 and P = 0.0018, respectively).
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Histological analysis of canine cutaneous mast cells
Two 5 lm tissue sections were stained with hematoxylin/eosin and toluidine
blue for histological examination and grading according to Patnaik et al. (1984).
Staining was performed according to an established protocol (Behmer et al.,
1976a,b).
Antibodies and immunohistochemistry
All MCTs were ﬁxed in 10% buffered formalin and parafﬁnized following the
standard protocol. Two mouse monoclonal antibodies were used for E-cadherin
detection – clone NCH38 (Dako) and clone HECD-1 (Invitrogen). Each of these anti-
bodies recognizes the extracellular domain of human E-cadherin (Nowak et al.,
2007; Huiping et al., 1999).
Immunohistochemical analysis was performed on 5 lm thick sections with
monoclonal antibodies against human E-cadherin (NCH-38 and HECD-1, both di-
luted at 1:100) by the peroxidase-conjugated streptavidin complex method (LSAB,
Dako), following the manufacturer’s instructions. Antigen retrieval for E-cadherin
was carried out by microwave treatment (3  4 min) in 10 mM citrate buffer at
pH 6.0. After an antigen retrieval step, sections were treated with 0.3% H2O2 in
methanol for 30 min to block endogenous peroxidase activity. Slides were then
rinsed in phosphate buffered saline (PBS)/Tween-20 and blocked for 30 min with
5% skimmed milk diluted in PBS/Tween-20. Sections were incubated overnight at
4 C with the primary antibody (dilution 1:100). The slides were then rinsed with
PBS/Tween-20 and incubated for 45 min with LSAB. Adjacent normal epithelial tis-
sues were used as internal positive controls. The primary antibody was replaced
with PBS for negative controls. The reaction was developed with the chromogen
diaminobenzidine tetrahydrochloride (DAB kit, Dako) and the sections were coun-
Fig. 2. (A) Photomicrograph immunostaining of E-cadherin (NCH-38) in all the MCT grades. Canine epithelial cells were highly positive for E-cadherin, and the
immunostaining was strictly localized to the cell membrane. (B) The control negative reaction is also shown. (C) Grade 1 MCTs were positive for E-cadherin in mast cell
membranes at the edges of the tumor. (D) However, the inner portion of well-differentiated MCTs (Grade 1) was positive for E-cadherin immunostaining in the cytoplasm of
mast cells. (E) We observed almost the same number of cells with positive cytoplasmic immunostaining in Grade 2 MCTs and Grade 1 MCTs. A decrease in the intensity of
immunostaining was observed in Grade 2 tumors compared with Grade 1 MCTs. (F) Grade 3 MCTs showed a signiﬁcant reduction in the number of cells with positive
cytoplasmic immunostaining for E-cadherin compared with well differentiated tumors (Grade 1 MCTs). With the use of anti-E-cadherin clone NCH-38, we observed that the
expression of E-cadherin was predominantly cytoplasmic in MCTs of all three grades, and the intensity of the expression decreased as MCT advanced to a higher grade.
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terstained with Mayer’s hematoxylin. The sections were observed and photo-
graphed (400 magniﬁcation) in 10 random ﬁelds of high cell density and a total
of 1300 cells were counted on each slide. The staining was scored as the presence
or absence of positive cells. The subcellular positivity of the immunostaining in
the membrane, cytoplasm and/or nuclei was noted.
Statistical analysis
For histological analysis, the data were expressed as the mean ± standard devi-
ation (SD). A non-parametric analysis among groups was performed using the Krus-
kal–Wallis test (Prism version 5, Graphpad Software). Survival curves were
generated by the Kaplan–Meyer method and survival rates were compared using
the log-rank test. All statistical analyses were performed using SPSS 11.5 statistical
software. Values of P < 0.05 were considered statistically signiﬁcant.
Results
Clinical history
There was no signiﬁcant effect of gender or age on tumor grade.
A total of seven dog breeds were included. Twelve of 18 dogs in
this study had died at the time data analysis was performed (nine
due to MCT and three of causes unrelated to MCT). All animals
diagnosed with Grade 3 MCT died due to the disease. At the end
of the study, three animals diagnosed with Grade 1 MCT and three
dogs diagnosed with Grade 2 MCT were still alive. The data are
summarized in Table 1. The survival time ranged from 2–
26 months for the animals with MCT 1; from 9–22 months for
the animals with Grade 2 MCT, and from 1–7 months for animals
with Grade 3 MCT. Statistical analysis of survival time is presented
in Fig. 1. There was a recurrence of disease in 33.3% (2/6) of Grade 1
MCT cases and in 33.3% (2/6) of Grade 2 MCT cases. All (6/6) Grade
3 MCT recurred.
In total, 40 tumors at different sites were observed, approxi-
mately half of which were single neoplasms and the other half
were multiple tumors with 2–9 nodules. In dogs with multiple
MCTs (i.e. neither metastases nor local tumor recurrence), survival
data were analyzed considering each tumor as a separate event
and by analyzing the data with only the ﬁrst tumor that had been
diagnosed. The most common anatomical location was the chest
27.5% (11/40), followed by the pelvic limbs 17.5% (7/40), lateral
abdomen 17.5% (7/40), head/neck 10% (4/40), ear canal 7.5% (3/
40), posterior thigh 7.5% (3/40), lateral thigh 5% (2/40), scrotum
5% (2/40) and digits 2.5% (1/40; Table 1).
Expression and localization of E-cadherin
Anti-human E-cadherin clone NCH38 antibody detected the
expression of E-cadherin in the membrane and cytoplasm of the
canine MCT cells (Fig. 2). The comparative analysis of E-cadherin
immunostaining by clone NCH38 revealed signiﬁcantly more posi-
tive cells with cytoplasmic labeling in Grade 1 MCT than in 3 MCT
(P = 0.021; Fig. 3). There were also more positive cells in Grade 2
than in Grade 3 MCT (P = 0.021; Fig. 3).
Immunohistochemistry using anti-human E-cadherin clone
HECD-1 antibody detected the expression of E-cadherin in the cell
membrane, cytoplasm and nucleus of canine MCT (Fig. 4). The
membrane immunostaining was observed only in Grade 1 MCTs,
while cytoplasmic and nuclear immunostaining was observed in
all three grades of MCT. There were fewer positive-staining cells
in the highest grade MCT. Comparative analysis of immunostaining
for E-cadherin clone HECD-1 revealed signiﬁcantly more cytoplas-
mic labeling in Grade 1 MCT compared with Grade 3 MCT
(P = 0.028). There were signiﬁcantly more positive cells for Grades
1 than for Grade 3 MCT (P < 0.001). However, when we compared
immunostaining within tumors of the same grade, there was no
difference between the cytoplasmic and nuclear markings in Grade
1 MCT (P = 0.07), Grade 2 MCT (P = 0.12), or Grade 3 MCT (P = 0.43).
The results showed that E-cadherin is differentially expressed in
canine cutaneous MCTs (Fig. 5).
Discussion
Despite the fact that cutaneous MCTs are one of the most fre-
quent and thus one of the most commonly studied neoplasms in
dogs, there are few studies characterizing the expression proﬁling
of cancer-related molecules in all the three grades MCT. There is
evidence that normal mast cells are attracted to the tumor site,
which could promote tumor growth through the release of inﬂam-
matory cytokines (Conti et al., 2007). Once mast cells are attracted
to tumors by chemo-attractants, such as stem cell factor (SCF), they
are triggered to secrete molecules that act as growth factors, stim-
ulating tumor growth, angiogenesis, and metastasis. Mast cells
thus promote the tumor microenvironment remodeling and tumor
growth, increasing the secretion of inﬂammatory chemicals and
the activity of NF-kappaB, which augments the suppression of T-
cells and natural killer cells in tumors (Huang et al., 2008).
In this study, the most commonly affected breed was the Boxer,
which is consistent with studies in the literature reporting a hered-
itary predisposition for animals related to the Bulldog, such as Box-
ers (O’Keefe, 1990; Simoes et al., 1994; Lemarié et al., 1995; Fox,
1998; London and Seguin, 2003; Misdorp, 2004; Costa et al.,
2007; Strefezzi et al., 2009; Costa-Casa Grande et al., 2008). Golden
Retrievers are also reported to be over-represented (Bostock and
Dye, 1973). It has been observed that animals >9 years are more
likely to be affected with tumor recurrence and death, and these
results agree with the ﬁndings reported by Cahalane et al.
(2004). Our results regarding anatomical site of MCTs also conﬁrm
previously published data showing that the most common sites are
the chest and perineum, followed by the distal parts of the limbs
and the head and neck (O’Keefe, 1990; Fox, 1998).
All of the animals diagnosed with Grade 3 MCTs died as a con-
sequence of tumor development. Tumor grade was not associated
with duration of tumor growth and survival time after tumor
recurrence ranged from 2–5 months regardless of the grade tumor.
The survival time of dogs with multiple MCTs was not signiﬁcantly
different to dogs with solitary tumors. Multiple tumors were more
prevalent in this study than previously reported in the literature
(3–14% from Macy, 1985; O’Keefe, 1990; Simoes et al., 1994).
In our study, Grade 1 MCTs were not different in terms of tumor
development, progression, recurrence and death rate compared to
Grade 2 MCT. However, when Grades 1 and 2 MCT were compared
to Grade 3 MCT, there was a signiﬁcant difference between the
groups, and Grade 3 disease carried a poor prognosis. These results
conﬁrm the histological ﬁndings observed in a study performed in
95 canine cutaneous MCTs reported by Kiupel et al. (2011), which
Fig. 3. Comparative analysis of cytoplasmic immunostaining of E-cadherin (NCH-
38) in all MCT grades. Error bars represent standard deviations. # Indicates P = 0.021
vs. MCT Grade 1.  Indicates P = 0.021 vs. MCT Grade 2.
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suggested that only two grades should be used to enhance agree-
ment between pathologists and provide a more meaningful
prognosis.
E-cadherin is a cell adhesion protein complex widely described
in the literature as a tumor suppressing agent, and loss of E-cad-
herin function contributes to lack of cellular differentiation and
growth of the primary lesion by several potential mechanisms
(Shiozaki et al., 1996; Brunetti et al., 2003; De Matos et al., 2007;
Gama et al., 2007). Tegoshi et al. (2000) demonstrated that E-cad-
herin was present in the cell membrane of normal mast cells. In
addition, an in vitro experimental study using anti-E-cadherin
antibodies indicated that it is functional and crucial for colony for-
mation in those cells. The expression of E-cadherin was also de-
tected in the human mast cell line HMC-1. It is possible that E-
cadherin is involved in interactions between mast cells and epithe-
lial cells, while other functions of its expression in mast cells re-
main to be elucidated (Nishida et al., 2003).
E-cadherin is found in the plasmatic membrane of normal or
well-differentiated canine mast cells. Our study demonstrated a
decrease of E-cadherin expression and subcellular localization of
cellular protein in more aggressive grades of canine MCTs, accom-
panied by reduced staining in the plasma membrane and de-
Fig. 4. (A) Photomicrograph of E-cadherin immunostaining (HECD-1) in all MCT grades. There was a positive cytoplasmic and nuclear immunostaining of epithelial cells and
positivity was not observed in the membrane. (B) The negative control reaction. (C) Positive immunostaining for E-cadherin was observed in the membrane and nucleus of
some well-differentiated mast cells on the edges of Grade 1 tumor. (D) In the inner portion of the same Grade 1 tumor, positive immunostaining was observed in the
cytoplasm and nucleus in most cells. (E) We observed almost the same number of cells with positive immunostaining for E-cadherin in Grade 2 MCTs and Grade 1 MCT.
However, a decrease in the intensity of immunostaining was observed in Grade 2 tumors. (F) Grade 3 MCTs showed a signiﬁcant reduction in the number of cells with positive
cytoplasmic and nuclear immunostaining for E-cadherin compared with well differentiated tumors (MCTs Grade 1).
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creased expression in the cytoplasm and/or nucleus as the tumor
took on a more aggressive phenotype. These results were found
for both of the antibodies used in this study (NCH-38 and HECD-
1 clones). The results indicated a change in the subcellular localiza-
tion of E-cadherin and decreased expression in higher grade MCTs,
corroborating the results reported by Salahshor et al. (2008) and
Chetty et al. (2008), which showed a frequent accumulation of E-
cadherin in the nucleus in the more aggressive stages of esopha-
geal squamous carcinoma and pancreatic tumors. The mechanisms
that lead to the loss of E-cadherin expression in the cell membrane
are still unclear. The disruption of cell-to-cell adhesion might be
mediated by several factors, such as digestion by proteases (Loch-
ter et al., 1997; Steinhusen et al., 2001), transcriptional repression
(Batlle et al., 2000; Cano et al., 2000; Yap et al., 2007), endocytosis
(Fujita et al., 2002), mutations in the E-cadherin gene (Oda et al.,
1994; Saito et al., 2001) and methylation of E-cadherin promoter
(Yoshiura et al., 1995).
The goal of any molecular research in cancer is to develop better
tools for disease control. Further studies in primary cell cultures
are ﬁrst required to better understand the molecular mechanisms
involved in decreased expression of E-cadherin in MCTs, and to
investigate possible means to reverse this.
Conclusions
This study demonstrated a decrease in the expression of E-cad-
herin in the most aggressive (Grade 3) canine cutaneous MCTs. In
addition, there was a change in subcellular localization of the
adhesion molecule in Grades 2 and 3 MCTs. The results suggest
that E-cadherin plays a crucial role in the behavior of MCT cells.
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